Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death

Hepatocellular carcinoma (HCC) has become the second leading cause of cancer related death, with an increasing death rate in recent years. For advanced HCC, sorafenib is the first-line FDA approved drug, with no more than 3 months' overall survival advantage. Recently, a novel strategy has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Linna, Zeng, Yanhua, Dai, Zichan, He, Wensheng, Ke, Huozhao, Lin, Qiaofa, Chen, Yan, Bu, Jingjing, Lin, Dexin, Zheng, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968850/
https://www.ncbi.nlm.nih.gov/pubmed/29805309
http://dx.doi.org/10.7150/ijbs.22220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968850/
https://www.ncbi.nlm.nih.gov/pubmed/29805309
http://dx.doi.org/10.7150/ijbs.22220

Ejemplares similares